argenx announces results of Annual General Meeting of Shareholders
11 Maggio 2021 - 11:00AM
May
11,
2021Breda, the
Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases and cancer, today
announced that the proposed resolutions presented at its Annual
General Meeting of Shareholders, held today at 10:00 a.m. CEST,
were duly passed.
As part of the approved resolutions:
- Yvonne Greenstreet has been
appointed as non-executive director to the Board of Directors for a
term of four (4) years;
- Anthony Rosenberg has been
re-appointed as non-executive director to the Board of Directors
for an additional term of four (4) years;
- the Board of Directors has been
authorized to issue additional shares up to a maximum of 10% of the
share capital of argenx for a period of 18 months from the Annual
General Meeting;
- the 2020 remuneration report as
well as the Company’s new remuneration policy has been
approved;
- Deloitte Accountants B.V. has been
appointed as the Company’s auditor for the 2021 financial
year.
In line with previous announcements, Dr. David Lacey has today
resigned from the board of directors and will transition to an
advisory role for the company.
The results of the votes and all documents
relating to the shareholders’ meeting will be available on the
Company’s website at www.argenx.com.
About argenx argenx is a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases and cancer.
Partnering with leading academic researchers through its Immunology
Innovation Program (IIP), argenx aims to translate immunology
breakthroughs into a world-class portfolio of novel antibody-based
medicines. argenx is evaluating efgartigimod in multiple serious
autoimmune diseases, and cusatuzumab in hematological cancers in
collaboration with Janssen. argenx is also advancing several
earlier stage experimental medicines within its therapeutic
franchises. argenx has offices in Belgium, the United States, Japan
and Switzerland. For more information,
visit www.argenx.com and follow us on LinkedIn at
https://www.linkedin.com/company/argenx/ and Twitter at
https://twitter.com/argenxglobal.
For further information, please
contact:
Investors: Beth
DelGiaccobdelgiacco@argenx.com
Michelle Greenblattmgreenblatt@argenx.com
Forward-looking
Statements
The contents of this announcement include
statements that are, or may be deemed to be, “forward-looking
statements.” These forward-looking statements can be identified by
the use of forward-looking terminology, including the terms
“believes,” “estimates,” “anticipates,” “expects,” “intends,”
“may,” “will,” or “should” and include statements argenx makes
concerning its 2021 business and financial outlook and related
plans; the therapeutic potential of its product candidates;
the intended results of its strategy and argenx’s, and its
collaboration partners’, advancement of, and anticipated clinical
development, data readouts and regulatory milestones and plans,
including the timing of planned clinical trials and expected data
readouts; the design of future clinical trials and the
timing and outcome of regulatory filings and regulatory
approvals. By their nature, forward-looking statements involve
risks and uncertainties and readers are cautioned that any such
forward-looking statements are not guarantees of future
performance. argenx’s actual results may differ
materially from those predicted by the forward-looking statements
as a result of various important factors, including the
effects of the COVID-19 pandemic, argenx’s expectations
regarding its the inherent uncertainties associated with
competitive developments, preclinical and clinical trial and
product development activities and regulatory approval
requirements; argenx’s reliance on collaborations with
third parties; estimating the commercial potential
of argenx’s product
candidates; argenx’s ability to obtain and maintain
protection of intellectual property for its technologies and
drugs; argenx’s limited operating history;
and argenx’s ability to obtain additional funding for
operations and to complete the development and commercialization of
its product candidates. A further list and description of these
risks, uncertainties and other risks can be found
in argenx’s U.S. Securities and Exchange Commission (SEC)
filings and reports, including in argenx’s most recent
annual report on Form 20-F filed with the SEC as well as subsequent
filings and reports filed by argenx with the SEC. Given these
uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this
document. argenx undertakes no obligation to publicly update or
revise the information in this press release, including any
forward-looking statements, except as may be required by
law.
- PR 210511 argenx Results Annual General Shareholders
meeting_FINAL
Grafico Azioni Argen X (EU:ARGX)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Argen X (EU:ARGX)
Storico
Da Apr 2023 a Apr 2024